本文選題：結(jié)核 + 肺　； 參考：《現(xiàn)代預(yù)防醫(yī)學(xué)》2017年06期

【摘要】：目的分析西安市全球基金耐多藥結(jié)核病項目實施效果,為今后制定耐多藥結(jié)核病控制策略提供依據(jù)。方法對項目執(zhí)行期間的報表、實驗室登記本、患者病案和追訪信息等進行分析。結(jié)果截至2014年6月底,共登記耐多藥結(jié)核病可疑者554例,554例均進行痰培養(yǎng),培養(yǎng)結(jié)果陽性356例(64.26%),對292例培養(yǎng)結(jié)果陽性者行藥敏實驗,共確診101例耐多藥結(jié)核病患者,其中新患者耐多藥檢出率16.18%,不同患者分類的耐多藥檢出率差異有統(tǒng)計學(xué)意義(χ~2=13.54,P0.01)。52例確診患者納入"項目",納入率51.49%;項目組治療成功率55.77%,非項目組治療成功率22.45%,差異有統(tǒng)計學(xué)意義(χ~2=11.71,P0.01);項目組患者6月末痰涂片陰轉(zhuǎn)率60.78%,痰培養(yǎng)陰轉(zhuǎn)率54.90%,12月末痰涂片陰轉(zhuǎn)率65.31%,痰培養(yǎng)陰轉(zhuǎn)率63.27%。結(jié)論耐多藥高危人群篩查策略、定點醫(yī)院治療和疾控中心管理的防治模式是可行和高效的,項目實施為西安市耐多藥防治打下了基礎(chǔ),為今后的工作提供了指導(dǎo)和借鑒。
[Abstract]:Objective to analyze the effect of MDR-TB project in Xi'an Global Fund, and to provide evidence for formulating MDR-TB control strategy in the future.Methods the report form, laboratory register, patient's medical record and information of follow-up were analyzed.Results by the end of June 2014, 554 suspected cases of MDR-TB were treated with sputum culture, 356 cases were positive and 64.260.292 cases of MDR-TB were tested by drug sensitivity test, 101 cases of MDR-TB were diagnosed.The detection rate of multidrug resistance in new patients was 16.18. The difference of multidrug resistance rate among different patients was statistically significant (蠂 ~ 2 ~ 2 ~ (13.54)) (P < 0.01). 52 patients with definite diagnosis were included in "project", the inclusion rate was 51.49.The success rate of project group was 55.77 and that of non-project group was 22.45.The sputum smear negative conversion rate in the project group was 60.78 at the end of June, the sputum culture negative conversion rate was 54.90 and the sputum smear negative conversion rate was 65.31 at the end of December, and the sputum culture negative conversion rate was 63.27.Conclusion the screening strategy of multidrug resistance high risk population, the treatment mode of designated hospital and the management mode of CDC are feasible and efficient. The implementation of the project lays a foundation for the prevention and treatment of multidrug resistance in Xi'an, and provides guidance and reference for future work.
【作者單位】： 西安市疾病預(yù)防控制中心;
【基金】：國家自然科學(xué)基金項目資助(項目編號:81272490) 陜西省社會發(fā)展科技攻關(guān)項目資助(項目編號:2015SF092)
【分類號】：R52

【相似文獻】

相關(guān)期刊論文 前10條

1 馬偉路,羅智;耐藥和耐多藥結(jié)核病及其控制[J];臨床肺科雜志;2000年01期

2 于維琴;耐多藥結(jié)核病的處理[J];臨床肺科雜志;2000年03期

3 曾國武;78例耐多藥結(jié)核病臨床分析[J];醫(yī)學(xué)文選;2000年05期

4 何國鈞;新世紀(jì)耐多藥結(jié)核病分子生物學(xué)診斷的重要性[J];中華傳染病雜志;2001年06期

5 肖成志,李群輝,李拯民,傅瑜;耐多藥結(jié)核病的治療[J];臨床肺科雜志;2001年03期

6 全國結(jié)核病胸部疾病科研協(xié)作組;耐多藥結(jié)核病治療的研究方案[J];臨床肺科雜志;2001年03期

7 C.Conover,R.Ridzon,S.Valway,L.Schoenstadt,J.McAuley,I.Onorato,W.Paul,an investigative team ,王海東;美沙酮治療規(guī)程中耐多藥結(jié)核病的暴發(fā)[J];結(jié)核與肺部疾病雜志(中文版);2001年02期

8 陸強,王樞傳;耐多藥結(jié)核病的研究進展[J];天津藥學(xué);2002年01期

9 李一耕;我國耐多藥結(jié)核病研究的現(xiàn)狀與思考[J];新醫(yī)學(xué);2003年11期

10 張立興 ,屠德華;加強預(yù)防和合理治療耐多藥結(jié)核病[J];中國防癆雜志;2003年01期

相關(guān)會議論文 前10條

1 馬s，

本文編號：1755659